In conclusion, our study suggests that VCAM-1, MCP-1 and ADMA can be useful biomarkers to identify the presence of ILD in patients with RA, as well as to discriminate between RA-ILD+ and IPF, contributing to the early diagnosis of RA-ILD+. Here, CCL2 is linked to rheumatoid arthritis.